期刊文献+

5-FU对人喉癌细胞系Hep-2裸鼠移植瘤治疗作用的实验观察 被引量:1

The Antitumor Effects of 5-FU on Human Laryngeal Squamous Carcinoma Line Hep-2 Transplanted in Nude Mice
下载PDF
导出
摘要 目的观察5-氟尿嘧啶对人喉癌裸鼠移植瘤的治疗作用,为临床喉癌的化学药物治疗提供实验依据。方法将10只荷瘤裸鼠随机分为2组,治疗组给予5-氟尿嘧啶30mg/kg腹腔注射;对照组给予生理盐水0.2ml腹腔注射,连续给药7天后改为隔日给药,治疗后30天实验结束。观察移植瘤的生长特性和裸鼠体重增长值及移植瘤的光镜和电镜切片。结果与对照组相比,治疗组肿瘤体积增长较对照组缓慢,瘤体积和重量均明显低于对照组,统计学上有显著性差异(P<0.05),表明5-FU可有效抑制人喉癌裸鼠移植瘤的生长。治疗前后裸鼠体重增长值差别无显著性意义(P>0.05)。光镜和电镜观察治疗组移植瘤主要呈坏死改变。结论5-氟尿嘧啶可有效抑制人喉癌细胞系Hep-2裸鼠移植瘤的生长,体积抑瘤率为60.70%,重量抑瘤率达65.95%。抗肿瘤作用的主要形态学改变主要是药物直接作用于肿瘤细胞导致细胞的坏死。 Objective To determine the effects of 5-FU on the tumor growth of human laryngeal carcinoma llne Hep-2 transplanted in nude mice and guide the clinical chemotherapy in laryngeal carcinoma. Methods The 10 mice bearing substaneous transplanted tumour were divided into two groups randomly. The treatedgroup were given 5-FU (30mg/kg) by abdominal administration for consecutively 7 days, then once every other day. The mice's condition and the character of tumour growth were evaluated. The his-topathological studies with light and transmission microscopy was also done. Results The growth of the carcinoma implanted in the nude mice were significantly inhibited in the treated group. Compared with the control group, the implanted tumours were significantly reduced in weight and volume in mice treated with 5-FU (P〈0.05 ) There was no significantly difference in weight increasing between the two group (P 〉0.05) . The main morphological character of the treated tumour is nerosis. Conclusions 5-FU could suppress the tumour growth and the growth inhibition rate could reach 60.70% ( turnout volume) and 65.95% (tumour weight) Inducing tumour cell nerosis may be the main morphological change of 5-FU's antitumour mechanism in larygeal carcinoma.
出处 《锦州医学院学报》 2005年第6期44-47,共4页 Journal of Jinzhou Medical College
关键词 5-FU 喉癌 裸鼠 移植 5-FU laryngeal carcinoma transplant nude mice
  • 相关文献

参考文献5

  • 1Laccourreye O,Bssot V,Brasnu D.Exclusive chemotherapy in T1-T3N0 cancers of the vocal cord with complete clinical response after neoadjuvant treatment with a cisplatin-fluorouracil combination.[J]Press Med,1999,24(29):1337-1340.
  • 2Lore JM Jr,Diaz-Ordaz E,Spaulding M.Improved survival with preoperative chemotherapy followed by resction uncompromised by tumour response for advanced squamous cell carcinoma of the head and neck[J]Am J Surg,1995,170(5):506-511.
  • 3Laccourreye O,Brasnu D,Bassot V,Cisplatin-fluorouracil exclusive chemotherapy for T1-T3 N0 glottic squamous cell carcinoma complete clinical response five year results.[J]Clin Oncol 1996,14(8):2331-2336.
  • 4Adelatein DJ,Saxton Jp,Lavertu P.A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy with radiotherapy alone in respectable stage III and IV squamous cell head and neck cancer,preliminary results.[J]Head Neck.1997,19(7):567-575.
  • 5Sarini J,Bocciolini C,Fournier.Induction chemotherapy and laynx preservation:is such practice useful Bull[J]Cancer,2002,89(4):411-417.

同被引文献20

  • 1张效文,严名,王芷芬,等.用Q值估计合并用药效果的新方法:双30法[J].上海第二医科大学学报,1985,5(5):353-354.
  • 2Tamarit Conejeros JM, Carrasco Llatas M, EstelMs Ferriol E, et al.Supraglottic and glottie carcinomas. Study of the incidence in the last 31 years [J]. Acta Otorrinolaringol Esp, 2007,58 (10):449-453.
  • 3Trzcieniecka-Green A, Bargiel-Matusiewicz K, Borezyk J.Quality of life of patients after laryngectomy [J].J Physiol Pharmacol, 2007,58(Suppl 5):699-704.
  • 4Pentheroudakis G, Nicolaou I, Kotoula V, et al. Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx [J]. Oral Oncol, 2012,48 (8):709-16.
  • 5Salgaller ML.Technology evaluation:bevacizumab, Genen- tech/Roche J [J] . Curr Opin Mol Ther,2003,5(6): 657- 667.
  • 6De Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer [J]. Oncology,2005,69(suppl 3):46-56.
  • 7Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies [J]. Ann Pharmacother,2004,38(7-8):1258-1264.
  • 8Yang H, Jager MJ, Grossniklaus HE. Bevacizumah suppression of establishment of micrometastases in experi- mental ocular melanoma [J]. Invest Ophthalmol Vis Sci, 2010,51(6):2835-2842.
  • 9Franchin G, Vaccher E, Gobitti C, et al.Neoadjuvant accelerated chemotherapy followed by hyperfraetionated radiation therapy in patients with operable,locally advanced head and neck carcinoma [J].Oral Oncology,2005,41 (5): 526-533.
  • 10Blons H, Cabelguenne A, Camot R, et al.Microsatellite analysis and response to chemotherapy in head and neck squamous cell carcinomas[J].Int J Cancer, 1999,84(4):410- 415.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部